Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
McKinsey
AstraZeneca
Mallinckrodt
Moodys

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

BEVYXXA Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Bevyxxa, and when can generic versions of Bevyxxa launch?

Bevyxxa is a drug marketed by Portola Pharms Inc and is included in one NDA. There are ten patents protecting this drug.

This drug has one hundred and twenty-six patent family members in thirty-one countries.

The generic ingredient in BEVYXXA is betrixaban. One supplier is listed for this compound. Additional details are available on the betrixaban profile page.

US ANDA Litigation and Generic Entry Outlook for Bevyxxa

Bevyxxa will be eligible for patent challenges on June 23, 2021. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 29, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Drug patent expirations by year for BEVYXXA
Drug Prices for BEVYXXA

See drug prices for BEVYXXA

Generic Entry Opportunity Date for BEVYXXA
Generic Entry Date for BEVYXXA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for BEVYXXA
Drug ClassFactor Xa Inhibitor
Mechanism of ActionFactor Xa Inhibitors
Synonyms for BEVYXXA
330942-05-7
4CA-0269
74RWP7W0J9
942B057
AB0027977
AB1008465
ABP000384
AC-30214
AKOS005146070
AN-3565
API0007103
BC638590
BCP01903
BCP9000395
BDBM50249298
Benzamide, N-(5-chloro-2-pyridinyl)-2-((4-((dimethylamino)iminomethyl)benzoyl)amino)-5-methoxy-
Betrixaban
Betrixaban (USAN)
Betrixaban [USAN:INN]
betrixaban/
CHEBI:140421
CHEMBL512351
compound 11 [PMID: 19297154]
CS-2481
D08873
DB12364
EX-A358
FT-0663094
GTPL9602
HY-10268
KB-75507
KS-00000645
MolPort-009-682-948
N-(5-Chloro-2-pyridinyl)-2-[[4-[(dimethylamino)iminomethyl]benzoyl]amino]-5-methoxybenzamide
N-(5-chloro-2-pyridyl)-2-[[4-(N,N-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxy-benzamide
N-(5-Chloropyridin-2-yl)-2-((4-(N,N-dimethylcarbamimidoyl)benzoyl)amino)-5- methoxybenzamide
N-(5-chloropyridin-2-yl)-2-({[4-(N,N-dimethylcarbamimidoyl)phenyl]carbonyl}amino)-5-methoxybenzamide
N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide
N-(5-Chloropyridin-2-yl)-2-[[4-(N,N-dimethylcarbamimidoyl)benzoyl]amino]-5-methoxybenzamide
N-(5-chloropyridin-2-yl)-2-[4-(N,N-dimethylcarbamimidoyl)benzamido]-5-methoxybenzamide
NCGC00371122-02
PRT 054021
PRT-054021
PRT054021
QCR-99
SB16951
SCHEMBL158591
UNII-74RWP7W0J9
VA11998
W9900
ZINC30691754

US Patents and Regulatory Information for BEVYXXA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-002 Jun 23, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 RX Yes No   Start Trial   Start Trial   Start Trial
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 RX Yes No   Start Trial   Start Trial Y   Start Trial
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-002 Jun 23, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-002 Jun 23, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
AstraZeneca
Dow
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.